National psoriasis foundation medical board consensus statement on biologic therapies - 21/08/11
Doi : 10.1016/j.jaad.2004.10.774
Le texte complet de cet article est disponible en PDF.
Alice Gottlieb, MD, PhD, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick, NJ, United States; Jerry Bagel, MD, East Windsor, NJ, United States; Craig Leonardi, MD, St. Louis, MO, United States; David Pariser, MD, Norfolk, VA, United States
Le texte complet de cet article est disponible en PDF.| P2777 Dr. Gottlieb has received commercial support from Amgen, Inc., Biogen Idec, Centocor, Genentech, and Abbott; received research funding from Amgen, Wyeth, Biogen Idec, Centocor, Genentech, and Abbott; and has been a consultant and/or speaker for Amgen, Wyeth, Biogen Idec, and Abbott. Dr. Bagel has received commercial support from Amgen, Biogen Idec, and Centocor and has been a consultant and/or speaker for Amgen, Biogen Idec, and Genentech. Dr. Leonardi has received commercial support from Amgen, Biogen Idec, Centocor, Genentech, Abbott, and Serono; received research funding from Amgen, and Genentech; and has been a consultant and/or speaker for Amgen, Centocor, Genentech, and Serono. Dr. Pariser has received commercial support from Amgen, Biogen Idec, Centocor, Genentech, and Abbott; received research funding from Amgen, Biogen Idec, and Centocor; and has been a consultant and/or speaker for Amgen, Genentech, and Abbott. |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 52 - N° 3S
P. P191 - mars 2005 Retour au numéro
Article précédent
- Low-dose (25 mg) acitretin in the treatment of psoriasis
- Preliminary results of educate, a multicenter, community-based, open-label study of the effect of etanercept on skin and joint disease in patients with psoriatic arthritis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?